MET in gastric cancer - discarding a 10% cutoff rule

Aims We aimed to develop a putative predictive biomarker score for future hepatocyte growth factor receptor (MET)‐targeted therapy of gastric cancer (GC). Methods and results MET expression and MET amplification were analysed by immunohistochemistry (IHC) and chromogenic in‐situ hybridization (CISH)...

Full description

Saved in:
Bibliographic Details
Published in:Histopathology 2016-01, Vol.68 (2), p.241-253
Main Authors: Metzger, Marie-Luise, Behrens, Hans-Michael, Böger, Christine, Haag, Jochen, Krüger, Sandra, Röcken, Christoph
Format: Article
Language:English
Subjects:
Aged
Biomarkers, Tumor - genetics
Biomarkers, Tumor - metabolism
Class I Phosphatidylinositol 3-Kinases - genetics
Cohort Studies
Female
Gastric cancer
Gene Amplification
Humans
Immunohistochemistry
In Situ Hybridization
Kaplan-Meier Estimate
Male
Medical prognosis
MET
Original
predictive biomarker
Prognosis
Proto-Oncogene Proteins c-met - genetics
Proto-Oncogene Proteins c-met - metabolism
Proto-Oncogene Proteins p21(ras) - genetics
Retrospective Studies
Stomach Neoplasms - diagnosis
Stomach Neoplasms - genetics
Stomach Neoplasms - metabolism
Stomach Neoplasms - pathology
targeted therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aims We aimed to develop a putative predictive biomarker score for future hepatocyte growth factor receptor (MET)‐targeted therapy of gastric cancer (GC). Methods and results MET expression and MET amplification were analysed by immunohistochemistry (IHC) and chromogenic in‐situ hybridization (CISH) in 470 GC patients. Immunostaining was documented with the HistoScore. The percentage area of MET‐amplified tumour cell clones was assessed by virtual microscopy. The expression of MET was heterogeneous in primary and metastatic GC. Immunostaining intensity (MET‐IHC 2+/3+) correlated with MET amplification and a positive MET status was defined by a combination of MET‐IHC 2+ or 3+ with MET amplification, or MET‐IHC 3+ without MET amplification. The prognostic significance of the MET status was independent from the percentage area of positive tumour cells (e.g.
ISSN:0309-0167
1365-2559
DOI:10.1111/his.12745